April’s issue of CSH Protocols features a set of articles on the production and use of retroviral vectors for gene transfer from Kenneth Cornetta, Karen Pollok and Dusty Miller. Retroviral Vectors for Gene Transfer provides an overview of the subject, drawing on the more than twenty years of experience researchers have with the use of these vectors. The advantages of retroviral vectors are detailed (efficiency, integration and ease of production) along with the disadvantages (inactivation, a requirement for cell division and possible oncogenic activation). The authors discuss important aspects of vector design and choice of packaging cell lines.
Four protocols are provided, two for production of viral vectors, and two for their use in transducing cells. Detailed methods are offered for Retroviral Vector Production by Transient Transfection, and for the Generation of Stable Vector-Producing Cells. Once vectors are generated, they can easily be used to Transduce Cell Lines which are actively proliferating. However, using retroviral vectors with primitive progenitor or stem cells, which are not continuously dividing, is much less efficient. In Transduction of Primary Hematopoietic Cells by Retroviral Vectors, the authors describe two interventions to improve efficiency of transfer, the use of cytokines and other growth factors to stimulate cell cycling, and the use of matrix proteins to mediate colocalization of target cells and vector.
April 10, 2008 at 7:34 pm
I would love to have a look at the protocol. Unfortunately, our university’s access has expired.
April 11, 2008 at 8:17 am
The only way your librarian can find out that there’s material you want access to is to let them know. CSH Protocols offers free 3 month trials to institutions, more information here:
http://www.cshprotocols.org/subscriptions/procedure.dtl
If your institution has already had a trial, then you need to let your librarian know that it’s a journal you want to subscribe to, otherwise, they’ll never know.
April 27, 2008 at 12:15 am
Retroviral gene transfer protocols have no clinical relevance, too dangerous to be on trial. For research purposes it’s kool.
Retroviral vectors in gene therapy – is it the end of the road?